CellerateRX® - Uncommon Technology / Unlimited Potential

CellerateRx Activated Collagen targets a multi-billion dollar domestic and international wound care market with over 60% profit margins. A large part of the growth in the wound care markets is from diabetic ulcers. The advanced wound care market is over $5B worldwide now and forecasts show that by 2025 just the Global Diabetic Market could have in excess of 48 million patients that could be a candidate for CellerateRX.

CellerateRX®'s activated collagen (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to prepare the collagen for use in the wound healing process. In people with compromised health or circulation, the difference in wound healing can be significant. You can read through numerous evidence-based studies on the www.celleraterx.com website.

CellerateRX® is FDA cleared for all wound types except for 3rd degree burns and is available in both powder (95% collagen) and gel (65% collagen) form. The products have HCPC codes for reimbursement by Medicare and other insurers. It is active in all 4 phases of wound healing. In addition to being used in healthcare settings throughout the country, CellerateRX® is easily applied by patients by themselves at home. CellerateRX® is safe, non-toxic, and easy to use. Wound Care Innovations, LLC (WCI), a wholly owned subsidiary of WNDM, has the exclusive worldwide licensing and distribution rights for CellerateRX advanced wound care collagen products.

Diabetes A worldwide epidemic, a prime market for CellerateRX
According the IDF, approximately 285 million people will live with diabetes in 2010. WHO projects this to grow to 360 million by 2030.
Diabetes affects approximately 24 million Americans, 57 million are pre-diabetic and likely to develop diabetes within 10 years.
15%-20% of diabetics will develop at least one ulcer.
There are 82,000 leg amputations due to diabetes every year in the U.S. at a cost of $11.5 billion.
Diabetes cost the U.S. $174 billion per year - $116 billion in direct medical costs. If not curbed, 1 in 3 to 1 in 5 Americans by 2050 (CBC; 10/2010).
Every 30 seconds somewhere in the world someone loses a leg to diabetes.